Search for other papers by M. Schlumberger in
Google Scholar
PubMed
Search for other papers by L. Bastholt in
Google Scholar
PubMed
Search for other papers by H. Dralle in
Google Scholar
PubMed
Search for other papers by B. Jarzab in
Google Scholar
PubMed
Search for other papers by F. Pacini in
Google Scholar
PubMed
Search for other papers by J.W.A. Smit in
Google Scholar
PubMed
Methods of Development of Evidence-Based Guidelines The European Thyroid Association (ETA) Executive Committee launched a taskforce to produce guidelines on the treatment of metastatic medullary thyroid cancer (MTC). A chairperson was selected
Search for other papers by R. Elisei in
Google Scholar
PubMed
Search for other papers by M. Alevizaki in
Google Scholar
PubMed
Search for other papers by B. Conte-Devolx in
Google Scholar
PubMed
Search for other papers by K. Frank-Raue in
Google Scholar
PubMed
Search for other papers by V. Leite in
Google Scholar
PubMed
Search for other papers by G.R. Williams in
Google Scholar
PubMed
Introduction Several guidelines have already been published on the diagnosis, management, and treatment of medullary thyroid cancer (MTC) [ 1 , 2 , 3 , 4 ], but there are no guidelines devoted specifically to RET genetic screening in
Search for other papers by Lars Bastholt in
Google Scholar
PubMed
Department of Nuclear Medicine, University Hospital Würzburg, Würzburg
Search for other papers by Michael C. Kreissl in
Google Scholar
PubMed
Search for other papers by Dagmar Führer in
Google Scholar
PubMed
Search for other papers by Ana L. Maia in
Google Scholar
PubMed
Search for other papers by Laura D. Locati in
Google Scholar
PubMed
Search for other papers by Léa Maciel in
Google Scholar
PubMed
Search for other papers by Yi Wu in
Google Scholar
PubMed
Search for other papers by Kevin N. Heller in
Google Scholar
PubMed
Search for other papers by Alan Webster in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Introduction Medullary thyroid cancer (MTC) is a malignancy of the parafollicular C cells of the thyroid gland, and it accounts for an estimated 4% of thyroid cancers [ 1 , 2 ]. MTC can only be cured by surgery and, until recently, the
Search for other papers by Laura Moss in
Google Scholar
PubMed
Search for other papers by Catrin Cox in
Google Scholar
PubMed
Search for other papers by Jonathan Wadsley in
Google Scholar
PubMed
Search for other papers by Kate Newbold in
Google Scholar
PubMed
Search for other papers by Mark W.J. Strachan in
Google Scholar
PubMed
Search for other papers by Maralyn Druce in
Google Scholar
PubMed
Search for other papers by Neil Tolley in
Google Scholar
PubMed
Search for other papers by Kathryn Graham in
Google Scholar
PubMed
Search for other papers by Sarah Jefferies in
Google Scholar
PubMed
Search for other papers by Lydia Fresco in
Google Scholar
PubMed
Search for other papers by Suganya Sivabalasingham in
Google Scholar
PubMed
Search for other papers by Alistair Balfour in
Google Scholar
PubMed
Search for other papers by Chris Hurt in
Google Scholar
PubMed
Introduction Medullary thyroid cancer (MTC) is a rare variant of thyroid cancer with different aetiology, presentation, treatment and symptoms compared to the more common differentiated thyroid cancers (DTC). Based on Cancer Research UK (CRUK
Search for other papers by Zoe A. Efstathiadou in
Google Scholar
PubMed
Search for other papers by Charalambos Tsentidis in
Google Scholar
PubMed
Search for other papers by Alexandra Bargiota in
Google Scholar
PubMed
Search for other papers by Vasiliki Daraki in
Google Scholar
PubMed
Search for other papers by Kalliopi Kotsa in
Google Scholar
PubMed
Search for other papers by Georgia Ntali in
Google Scholar
PubMed
Search for other papers by Labrini Papanastasiou in
Google Scholar
PubMed
Search for other papers by Stelios Tigas in
Google Scholar
PubMed
Search for other papers by Konstantinos Toulis in
Google Scholar
PubMed
Search for other papers by Kalliopi Pazaitou-Panayiotou in
Google Scholar
PubMed
Search for other papers by Maria Alevizaki in
Google Scholar
PubMed
Introduction Medullary thyroid cancer (MTC) is a malignant tumor arising from the thyroid parafollicular C cells. It is considered a rare neoplasm since it accounts for just 1–2% of all thyroid cancers [ 1 , 2 ]. Prognosis depends on disease
Search for other papers by Carla Gambale in
Google Scholar
PubMed
Search for other papers by Alessandro Prete in
Google Scholar
PubMed
Search for other papers by Chiara Romei in
Google Scholar
PubMed
Search for other papers by Alessandro Celi in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Antonio Matrone in
Google Scholar
PubMed
Established facts Selpercatinib, a highly selective RET inhibitor, has demonstrated notable efficacy in advanced/progressive RET-mutant medullary thyroid cancer patients. Despite a more tolerable toxicity profile than multikinase
UMR9019, Genome Integrity and Cancers, CNRS, Villejuif, France
Search for other papers by Camille Buffet in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
CHU Nantes/ICO, Saint-Herblain, France
Search for other papers by Françoise Kraeber-Bodéré in
Google Scholar
PubMed
CHU Nantes/ICO, Saint-Herblain, France
Search for other papers by Caroline Bodet-Milin in
Google Scholar
PubMed
Université de Paris, Paris, France
Search for other papers by Laure Cabanes in
Google Scholar
PubMed
Department of Radiology, AP-HP, Hôpital Cochin, Paris, France
Search for other papers by Anthony Dohan in
Google Scholar
PubMed
Search for other papers by Pascal Leprince in
Google Scholar
PubMed
Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute, Villejuif, France
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Department of Medical Oncology, AP-HP, Hôpital Cochin, Paris, France
Search for other papers by Olivier Huillard in
Google Scholar
PubMed
Université de Paris, Paris, France
Department of Endocrinology, AP-HP, Hôpital Cochin, Paris, France
Search for other papers by Lionel Groussin in
Google Scholar
PubMed
from medullary thyroid cancers (MTC) are uncommon. Their frequency in large autopsy series in patients with thyroid cancers is low, between 0 and 5% [ 1 - 5 ]. Given the rarity of this metastatic location, the outcome remains unclear. The average length
Search for other papers by Simona Censi in
Google Scholar
PubMed
Search for other papers by Jacopo Manso in
Google Scholar
PubMed
Search for other papers by Teresa Benvenuti in
Google Scholar
PubMed
Search for other papers by Ilaria Piva in
Google Scholar
PubMed
Search for other papers by Maurizio Iacobone in
Google Scholar
PubMed
Search for other papers by Alberto Mondin in
Google Scholar
PubMed
Search for other papers by Francesca Torresan in
Google Scholar
PubMed
Search for other papers by Daniela Basso in
Google Scholar
PubMed
Search for other papers by Gino Crivellari in
Google Scholar
PubMed
Search for other papers by Stefania Zovato in
Google Scholar
PubMed
Search for other papers by Caterina Mian in
Google Scholar
PubMed
Introduction Medullary thyroid cancer (MTC) originates from parafollicular C-cells and represents 2% of all thyroid malignancies and 0.4–1.4% of all thyroid nodules ( 1 ). MTC is sporadic in 75–80% of cases or manifests as a hereditary tumor
Search for other papers by Luciana Puleo in
Google Scholar
PubMed
Search for other papers by Laura Agate in
Google Scholar
PubMed
Search for other papers by Irene Bargellini in
Google Scholar
PubMed
Search for other papers by Giuseppe Boni in
Google Scholar
PubMed
Search for other papers by Paolo Piaggi in
Google Scholar
PubMed
Search for other papers by Claudio Traino in
Google Scholar
PubMed
Search for other papers by Tommaso Depalo in
Google Scholar
PubMed
Search for other papers by Giulia Lorenzoni in
Google Scholar
PubMed
Search for other papers by Francesca Bianchi in
Google Scholar
PubMed
Search for other papers by Duccio Volterrani in
Google Scholar
PubMed
Search for other papers by Sandra Brogioni in
Google Scholar
PubMed
Search for other papers by Valeria Bottici in
Google Scholar
PubMed
Search for other papers by Maurizia Rossana Brunetto in
Google Scholar
PubMed
Search for other papers by Barbara Coco in
Google Scholar
PubMed
Search for other papers by Eleonora Molinaro in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Introduction Medullary thyroid cancer (MTC) is a neuroendocrine tumor arising from parafollicular or calcitonin-producing C cells that retain the biochemical and pathological features of the cells from which it derives. MTC accounts for 3
Search for other papers by Grace Segall in
Google Scholar
PubMed
Search for other papers by Ravinder Singh in
Google Scholar
PubMed
Search for other papers by Min-Hua Jen in
Google Scholar
PubMed
Search for other papers by Isaac Sanderson in
Google Scholar
PubMed
Search for other papers by Alex Rider in
Google Scholar
PubMed
Search for other papers by Katie Lewis in
Google Scholar
PubMed
Search for other papers by Urpo Kiiskinen in
Google Scholar
PubMed
Introduction Medullary thyroid cancer (MTC) is a rare neuroendocrine tumour derived from calcitonin-secreting parafollicular C cells ( 1 ) and accounts for approximately 2‒4% of thyroid cancers ( 2 , 3 , 4 , 5 ) but up to 15% of thyroid